GlobeNewsWire
31 Mar 2026, 20:05 UTC · 33w ago
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
Impact · against what's priced in
The acceptance of the SIM0505 abstract for ASCO 2026 serves as a positive catalyst for NextCure and Simcere by establishing a concrete date for potential data validation. While it is early-stage (Phase 1), the confirmation of a major conference presentation typically drives speculative interest and validates progress in the CDH6 ADC pipeline.
- NXTC+0.40
No priced-in read yet





